Murine acid alpha-glucosidase: cell-specific mRNA differential expression during development and maturation
- PMID: 10233847
- PMCID: PMC1866561
- DOI: 10.1016/s0002-9440(10)65361-8
Murine acid alpha-glucosidase: cell-specific mRNA differential expression during development and maturation
Abstract
Acid alpha-glucosidase (GAA) cleaves the alpha1-4 and alpha1-6 glycosidic linkages of glycogen and related alpha-glucosyl substrates within lysosomes. Its deficiency results in glycogen storage disease type II (GSDII) variants including Pompe disease. To gain insight into the tissue patterns of involvement by glycogen storage in GSDII, GAA mRNA expression in mouse tissues was evaluated by Northern blot and in situ hybridization analyses. Extensive temporal and spatial variation of GAA mRNA was observed. During preterm maturation, GAA mRNA levels of whole mice progressively increased as assessed by Northern analysis. By in situ hybridization with GAA antisense mRNA, low signals were detected in most tissues throughout gestation. However, increased expression in specific cell types of different tissues was observed beginning at 16 days post coitum in developing brain neurons, primitive inner ear cells, and seminiferous tubular epithelium. In adult mice, whole-organ GAA mRNA levels were highest in brain, moderate in heart, liver, and skeletal muscle, and lowest in the series kidney > lung > testis > spleen. By in situ hybridization, the highest-intensity signals were in neurons of the central and peripheral nervous systems whereas neuroglial cells had only low-level signal. Signals of moderate intensity were in cardiomyocytes whereas low signals were in hepatocytes and skeletal muscle myocytes and very low in cells of the lungs, thymus, pancreas, spleen, and adrenal glands. However, testicular Sertoli cells and kidney tubular epithelial cells had significant signals even though surrounding cells had very low signals. The discrete temporal and spatial variations of GAA mRNA during development indicate different physiological roles for this enzyme in various cell types and developmental stages.
Figures



Similar articles
-
Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.Hum Gene Ther. 2005 Jan;16(1):68-80. doi: 10.1089/hum.2005.16.68. Hum Gene Ther. 2005. PMID: 15703490
-
Molecular cloning of acid alpha-glucosidase cDNA of Japanese quail (Coturnix coturnix japonica) and the lack of its mRNA in acid maltase deficient quails.Biochim Biophys Acta. 1997 Dec 31;1362(2-3):269-78. doi: 10.1016/s0925-4439(97)00092-6. Biochim Biophys Acta. 1997. PMID: 9540858
-
Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.Biochem Biophys Res Commun. 2000 Oct 5;276(3):917-23. doi: 10.1006/bbrc.2000.3555. Biochem Biophys Res Commun. 2000. PMID: 11027569
-
Gene Therapy for Pompe Disease: The Time is now.Hum Gene Ther. 2019 Oct;30(10):1245-1262. doi: 10.1089/hum.2019.109. Epub 2019 Sep 9. Hum Gene Ther. 2019. PMID: 31298581 Review.
-
Genetic defects in patients with glycogenosis type II (acid maltase deficiency).Muscle Nerve Suppl. 1995;3:S70-4. doi: 10.1002/mus.880181415. Muscle Nerve Suppl. 1995. PMID: 7603531 Review.
Cited by
-
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.Hum Gene Ther. 2012 May;23(5):460-72. doi: 10.1089/hum.2011.063. Epub 2012 Mar 29. Hum Gene Ther. 2012. PMID: 22260439 Free PMC article.
-
Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.J Gene Med. 2009 Oct;11(10):913-20. doi: 10.1002/jgm.1372. J Gene Med. 2009. PMID: 19621331 Free PMC article.
-
Lipid Involvement in Neurodegenerative Diseases of the Motor System: Insights from Lysosomal Storage Diseases.Front Mol Neurosci. 2017 Nov 3;10:356. doi: 10.3389/fnmol.2017.00356. eCollection 2017. Front Mol Neurosci. 2017. PMID: 29163032 Free PMC article. Review.
-
Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.Mol Genet Metab. 2011 Jun;103(2):107-12. doi: 10.1016/j.ymgme.2011.02.006. Epub 2011 Feb 13. Mol Genet Metab. 2011. PMID: 21397538 Free PMC article.
-
Genotype-phenotype correlation in Pompe disease, a step forward.Orphanet J Rare Dis. 2014 Aug 8;9:102. doi: 10.1186/s13023-014-0102-z. Orphanet J Rare Dis. 2014. PMID: 25103075 Free PMC article.
References
-
- Hers HG: α-Glucosidase in generalized glycogen-storage disease (Pompe’s disease). Biochem J 1963, 86:11-16 - PubMed
-
- Brown BI, Brown DH: The subcellular distribution of enzymes in type II glycogenosis and the occurrence of oligo α-1,4-glucan glucohydrolase in human tissues. Biochim Biophys Acta 1981, 110:124-133 - PubMed
-
- Hirschhorn R: Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. Scriver CR Beaudet AL Sly WL Valle D eds. The Metabolic and Molecular Bases of Inherited Disease. 1995, :pp 2443-2464 McGraw Hill, New York
-
- Mancall EL, Aponte GE, Berry RG: Pompe’s disease (diffuse glycogenosis) with neuronal storage. J Neuropathol Exp Neurol 1965, 24:85-96 - PubMed
-
- Hug G, Schubert WK: Glycogenosis type II. Arch Pathol 1967, 84:141-152 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous